BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34475740)

  • 1. Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn's disease: a systematic review and meta-analysis.
    Garg R; Mohan BP; Ponnada S; Regueiro M; Lightner AL; Click B
    Ann Gastroenterol; 2021; 34(5):691-698. PubMed ID: 34475740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn's Disease Patients.
    Li L; Jiang K; Lou D; Zhang M; Shi Y; Shen J; Fu X
    Eur Surg Res; 2023; 64(4):412-421. PubMed ID: 37598662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
    Abd El Aziz MA; Abdalla S; Calini G; Saeed H; Stocchi L; Merchea A; Colibaseanu DT; Shawki S; Larson DW
    J Crohns Colitis; 2022 Aug; 16(7):1079-1088. PubMed ID: 35045164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study.
    Shim HH; Ma C; Kotze PG; Seow CH; Al-Farhan H; Al-Darmaki AK; Pang JXQ; Fedorak RN; Devlin SM; Dieleman LA; Kaplan GG; Novak KL; Kroeker KI; Halloran BP; Panaccione R
    J Can Assoc Gastroenterol; 2018 Sep; 1(3):115-123. PubMed ID: 31294352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
    Shah RS; Bachour S; Jia X; Holubar SD; Hull TL; Achkar JP; Philpott J; Qazi T; Rieder F; Cohen BL; Regueiro MD; Lightner AL; Click BH
    J Crohns Colitis; 2021 Jul; 15(7):1142-1151. PubMed ID: 33388775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease.
    Lightner AL; McKenna NP; Tse CS; Hyman N; Smith R; Ovsepyan G; Fleshner P; Crowell K; Koltun W; Ferrante M; D'Hoore A; Lauwers N; Verstockt B; Spinelli A; DiCandido F; Raffals LE; Mathis KL; Loftus EV
    J Crohns Colitis; 2018 Mar; 12(4):402-407. PubMed ID: 29220430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
    Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
    J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Anti-Tumor Necrosis Factor-Alpha Therapy within 12 Weeks Prior to Surgery on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Cira K; Weber MC; Wilhelm D; Friess H; Reischl S; Neumann PA
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
    Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    MacDonald JK; Nguyen TM; Khanna R; Timmer A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
    Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
    Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis.
    Rosenfeld G; Qian H; Bressler B
    J Crohns Colitis; 2013 Dec; 7(11):868-77. PubMed ID: 23466411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis.
    Yang ZP; Hong L; Wu Q; Wu KC; Fan DM
    Int J Surg; 2014; 12(3):224-30. PubMed ID: 24394691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
    Newman KL; Johnson LA; Stidham RW; Higgins PDR
    Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis.
    Kopylov U; Ben-Horin S; Zmora O; Eliakim R; Katz LH
    Inflamm Bowel Dis; 2012 Dec; 18(12):2404-13. PubMed ID: 22467533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients.
    Lightner AL; Grass F; Alsughayer AM; Harmsen WS; Petersen M; Loftus EV
    Dis Colon Rectum; 2020 Jul; 63(7):934-943. PubMed ID: 32149787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.